Status:
TERMINATED
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Lead Sponsor:
Region Skane
Conditions:
Thyroid Neoplasms
Carcinoma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we ...
Detailed Description
Patients with Anaplastic Thyroid Cancer have a poor prognosis. We will treat the patients initially with our standard radiochemotherapy, which consists of doxorubicin 20mg fixed dose/week and hyperfra...
Eligibility Criteria
Inclusion
- cytologically or histologically verified anaplastic thyroid cancer
- completed standard therapy
- operated with R0 or R1 surgery
- Performance Status 0-2 (if pulmonary mets PS 0-1)
- normal wound healing
- neutrophils \> 1,5 million/ml
- platelets \> 100 million/ml
- bilirubin \< 2 ULN
- creatinin \< 150mikromol/L
Exclusion
- PS 3-4 (if pulmonary mets 2-4)
- R2 resection of primary tumor
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00804830
Start Date
April 1 2008
End Date
December 1 2014
Last Update
August 28 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Jubileumskliniken, Sahlgrenska universitetsjukhuset
Gothenburg, Sweden, 413 45
2
Dep of Oncology, Lund University Hospital
Lund, Sweden, 221 85
3
Karolinska University Hospital
Stockholm, Sweden, 17176